Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Sharma, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Reid, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Hoosen, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Garrett, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Beck, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Davidson, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
MacKenzie, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Brandt, U. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
Hecht, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
机构：
[1] Nevada Canc Inst, Las Vegas, NV USA
[2] UCSD, Moores Canc Ctr, La Jolla, CA USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Highlands Oncol Grp, Fayetteville, AR USA
[6] N Valley Hematol Oncol Med Grp, Northridge, CA USA
[7] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[8] Novartis Pharma AG, Basel, Switzerland
[9] Univ Calif Los Angeles, Ctr Comprehens Canc, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15115
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Reid, Tony R.
    Garrett, Christopher R.
    Beck, J. Thaddeus
    Davidson, Sheldon J.
    Mackenzie, Mary J.
    Brandt, Ulrike
    Rizvi, Syed
    Sharma, Sunil
    [J]. ANTICANCER RESEARCH, 2015, 35 (03) : 1567 - 1573
  • [2] Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102-Final report
    Shahda, S.
    Yu, M.
    Picus, J.
    Bufill, J. A.
    Harb, W. A.
    Burns, M.
    Spittler, A. J.
    Flynn, J.
    Zeng, Y.
    Vance, G. H.
    Wu, J.
    Currie, C. R.
    Loehrer, P. J.
    Chiorean, E. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102
    Myre, B.
    Yu, M.
    Picus, J.
    Bufill, J. A.
    Harb, W. A.
    Burns, M.
    Spittler, A. J.
    Zeng, Y.
    Currie, C. R.
    Chiorean, E. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [4] Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC)
    Carneiro, B. A.
    Bahary, N.
    Lembersky, B.
    Fakih, M.
    Krishnamurthi, S. S.
    Lancaster, S.
    Pinkerton, R.
    Crandall, T.
    Potter, D.
    Ramanathan, R. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).
    Townsend, Amanda Rose
    Pirc, Louise
    Cooper, Pamela
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Price, Timothy Jay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Townsend, A.
    Tebbutt, N.
    Karapetis, C.
    Cooper, P.
    Singhal, N.
    Yeend, S.
    Pirc, L.
    Joshi, R.
    Price, T. J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Irinotecan in second-line therapy of metastatic colorectal cancer
    Jäger, E
    Jäger, D
    Orth, J
    Knuth, A
    [J]. ONKOLOGIE, 2000, 23 : S15 - S17
  • [8] A phase 1B study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Price, T. J.
    Pirc, L.
    Cooper, P.
    Tebbutt, N.
    Karapetis, C.
    Singhai, N.
    Townsend, A. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S549 - S549
  • [9] A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
    Townsend, Amanda Rose
    Hardingham, Jennifer
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Joshi, Rohit
    Yeend, Sue
    Cooper, Pamela
    Dorward, Hilary
    Price, Timothy Jay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [10] Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
    Sobrero, A.
    Lenz, H-J.
    Eng, C.
    Scheithauer, W.
    Middleton, G.
    Chen, W.
    Esser, R.
    Nippgen, J.
    Burris, H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 163 - 163
12345